Objective: To investigate the efficacy and safety of clozapine in the treatment of levodopa-
induced dyskinesias (LID) in patients with severe Parkinson disease (PD). Methods: Fifty …

Objective: To assess the usefulness of low-dose olanzapine (2.5 to 7.5 mg/day) for
Levodopa-induced-dyskinesias (LID) in patients with PD. Methods: Ten patients with PD and …

Article abstract-The severity of parkinsonian motor disability and dyskinesias was evaluated
in seven levodopa-responsive patients with Parkinson's disease after an acute challenge …

We gave increasing daily doses of clozapine to six patients with advanced Parkinson's
disease (PD) and levodopa-induced dyskinesias. Clozapine reduced the daily dyskinesia …

Article abstract-Delusions and other manifestations of psychotic behavior are common side
effects in Parkinson's disease (PD) patients chronically treated with dopaminergic drugs …

Objective To assess dyskinesia frequency in a population-based cohort of patients with
Parkinson disease (PD). Dyskinesia complicates levodopa treatment and affects quality of …

Dyskinesias commonly appear during L‐dihydroxyphenylalanine (L‐DOPA) therapy of
advanced Parkinson's disease (PD) and can occur in both dose‐related and dose …

Levodopa is the most effective agent to alleviate motor dysfunction in Parkinson's disease
but its long-term use is associated with the development of dyskinesias. Although the …

Clozapine has been shown not only to be effective in ameliorating dopaminomimetic
psychosis but to improve parkinsonian symptomatology. Six parkinsonian patients with …

Objective: To clinically characterize the temporal relationship between dyskinesia and the
antiparkinsonian response when dyskinesia first emerges during long-term levodopa …